Market Intelligence Center  Dec 17  Comment 
A covered call identified by MarketIntelligececenter.com's patented algorithms on Jazz Pharmaceuticals Inc. (JAZZ) could yield about 7.45% (29.25% annualized, for comparison purposes only) in 93 days. Pair a long position in the stock with the...
TheStreet.com  Nov 6  Comment 
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.  TheStreet Ratings quantitative algorithm...
Market Intelligence Center  Sep 15  Comment 
Friday’s trading in Jazz Pharmaceuticals Inc. (JAZZ) gives options traders an opportunity for a 11.19% return. By selling the Dec. '14 $165.00 call and buying the Jan. '16 call at the $85.00 level for a net debit of $71.95, traders will book a...
TheStreet.com  Aug 19  Comment 
NEW YORK (TheStreet) --aJazz Pharmaceuticals shares are up 0.92% to $153.92 on Tuesday afterahaving coverage initiated with an "overweight" rating and $190 price target by analysts at JPMorgan . The firm believes that the pharmaceutical...
SeekingAlpha  Aug 6  Comment 
Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) Q2 2014 Results Earnings Conference Call August 5, 2014, 04:30 PM ET Executives Katherine Littrell - Head, IR Bruce Cozadd - Chairman and CEO Matt Young - SVP and CFO Russ Cox - EVP and...
Market Intelligence Center  Jul 24  Comment 
Jazz Pharmaceuticals Inc. (JAZZ) presents a trading opportunity that offers a 5.19% return in just 58 days. A covered call on Jazz Pharmaceuticals at the $145.00 level expiring on Sep. '14 offers an assigned return rate of 5.19% or 32.64%...
StreetInsider.com  Jul 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Jazz+%28JAZZ%29+Concert+%28CNCE%29+Initiate+First+Phase+1+Clinical+Trial+of+JZP-386/9676319.html for the full story.
StreetInsider.com  Jul 2  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Jazz+Pharmaceuticals+%28JAZZ%29+To+Acquire+Rights+To+Defibrotide+for+%2475M/9631892.html for the full story.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki